Divi’s Laboratories announced that the US Food and Drug Administration (US-FDA) conducted a general cGMP inspection of the Company’s Unit-II manufacturing facility at Chippada Village, Bheemunipatnam Mandal, Visakhapatnam, Andhra Pradesh from 11 July 2024 to 19 July 2024.

The US-FDA inspection is successfully completed with one procedural observation, which will be addressed in the stipulated period of time.

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content